BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19524629)

  • 1. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
    Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
    Seitz S; Schally AV; Treszl A; Papadia A; Rick F; Szalontay L; Szepeshazi K; Ortmann O; Halmos G; Hohla F; Buchholz S
    Anticancer Drugs; 2009 Aug; 20(7):553-8. PubMed ID: 19491659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
    Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
    Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
    Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S
    Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
    Katiyar SK; Meeran SM; Katiyar N; Akhtar S
    Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
    Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
    Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
    Hohla F; Buchholz S; Schally AV; Krishan A; Rick FG; Szalontay L; Papadia A; Halmos G; Koster F; Aigner E; Datz C; Seitz S
    Cancer Lett; 2010 Aug; 294(1):35-42. PubMed ID: 20156671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
    Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
    Kong M; Fan J; Dong A; Cheng H; Xu R
    Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
    Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
    Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
    Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.
    Ishibashi H; Suzuki T; Suzuki S; Niikawa H; Lu L; Miki Y; Moriya T; Hayashi S; Handa M; Kondo T; Sasano H
    Cancer Res; 2005 Jul; 65(14):6450-8. PubMed ID: 16024650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.
    Olbina G; Cieslak D; Ruzdijic S; Esler C; An Z; Wang X; Hoffman R; Seifert W; Pietrzkowski Z
    Anticancer Res; 1996; 16(6B):3525-30. PubMed ID: 9042216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
    Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
    Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
    Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.